Bladder Cancer Market

The global Bladder Cancer Market is valued at USD 4.2 Billion in 2023 and is projected to reach a value of USD 6.04 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 4.1% between 2024 and 2032.

Bladder Cancer Industry Highlights

• In 2023, North America accounted for 44.5% of the revenue market share due to the adoption of novel therapies and improved diagnostic techniques, bolstering patient outcomes and driving market growth due to increased awareness and early detection initiatives
• The Asia Pacific region is poised for significant expansion, with a significant CAGR projected throughout the forecast period
• Transitional Cell Bladder Cancer segment dominates the market in 2023 as it’s the most prevalent form of bladder cancer. This has spurred market players increase their efforts in research and innovative treatments
• In 2023, Chemotherapy emerged as the leading segment in the market, capturing a notable 41.2% market share
• Cystoscopy tests maintained a prominent market share in 2023 for the bladder cancer because cystoscopy is the primary method for direct visualization and biopsy collection, crucial for accurate diagnosis and monitoring of bladder cancer
• In 2023, Hospitals claimed the largest market share at 65.2% in the market due to their specialized facilities for cancer treatment, availability of skilled medical professionals, and comprehensive infrastructure supporting advanced diagnostic and therapeutic interventions

Understanding Bladder Cancer: Symptoms, Risks, and Recurrence

Bladder cancer is a rare type of cancer that originates in the lining of the bladder. Bladder cancer can recur after treatment, it is crucial for individuals to maintain regular follow-up appointments with their healthcare providers to monitor for any signs of recurrence.

Bladder cancer symptoms include:

• Blood in the urine (hematuria)
• Needing to urinate frequently
• Pain or discomfort during urination (dysuria)
• Pain in the lower back
• Recurring bladder infections

Several factors can elevate the risk of developing bladder cancer, including:

• Smoking, which introduces harmful chemicals from tobacco smoke that accumulate in the bladder
• Exposure to radiation
• Increasing age, particularly in individuals over 55
• Higher susceptibility in men compared to women
• Contact with certain industrial chemicals, such as those in dye, rubber, leather, textiles, and paint
• Persistent inflammation of the bladder
• Personal or family history of bladder cancer or Lynch syndrome

Regional Overview

Favorable reimbursement policies and strong regulatory support have led to North America’s market share to 44.5%

The incidence rate of bladder cancer is particularly high in the United States, which significantly impacts the market size. For instance, according to the American Cancer Society’s 2024 statistics, there were approximately 83,190 new cases of bladder cancer in the United States, with 63,070 cases in men and 20,120 cases in women. This high incidence is a result of the aging population and the high prevalence of risk factors like smoking and occupational exposures.

Nowadays bladder cancer patients can more easily access modern diagnosis and treatment options because of the reliable healthcare system and sophisticated healthcare infrastructure in North America. Modern medical facilities with cutting edge equipment guarantee that patients receive efficient care on schedule.

Advanced bladder cancer therapies are more accessible to patients because insurance coverage and reimbursement regulations in the area often support expensive cancer treatments. Promising bladder cancer treatments have been expedited into the market by regulatory bodies like the FDA, which have been proactive in awarding fast-track designations and breakthrough therapy approvals.

The implementation of various strategic initiatives by key market players is poised to drive market growth throughout the forecast period

• In August 2023, the U.S. Food and Drug Administration (FDA) granted approval for nivolumab as an adjuvant treatment for individuals with urothelial carcinoma (UC) who are at high risk of recurrence following radical resection, bolstering treatment options for bladder cancer patients.
• In February 2022, Astellas Pharma Inc. and Seagen Inc. unveiled preliminary findings from Cohort H of the EV-103 study, investigating PADCEV as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) ineligible for cisplatin-based treatment. These developments underscore the dynamic landscape of bladder cancer therapeutics and the concerted efforts to enhance treatment efficacy and patient outcomes.

Tests Overview

Cystoscopy segment leads the market due to its high sensitivity and specificity in detecting early-stage bladder cancer

Cystoscopy, a minimally invasive procedure, involves the insertion of a thin tube with a camera into the bladder to visually inspect the bladder lining for abnormalities, such as tumors or abnormal growths.

Cystoscopy is cost-effective diagnostic method is witnessing a surge in adoption driven by escalating incidences of bladder cancer and continuous product innovations by key market players. For instance, according to a study published in the World Journal of Urology in January 2022, titled "Explainable artificial intelligence (XAI): closing the gap between image analysis and navigation in complex invasive diagnostic procedures," approximately 1.2 million flexible cystoscopy procedures are conducted annually in the United States, further bolstering its utilization in bladder cancer diagnosis and contributing to market growth.

Strategic initiative undertaken by market players are poised to propel the expansion of the cystoscopy

• In February 2022, technological advancements in cystoscopy devices, such as the US FDA approval of Photocure ASA's enhanced Blue Light Cystoscopy (BLC) system for diagnosing non-muscle-invasive bladder cancer (NMIBC), are anticipated to foster market growth.

Government Initiatives Boosting Bladder Cancer: FDA Approvals, Innovative Detection Methods, and Health Insurance Coverage

• In January 2024, the U.S. Food and Drug Administration approved erdafitinib (Balversa, Janssen Biotech) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as identified by an FDA-approved companion diagnostic test, whose disease has progressed following at least one prior line of systemic therapy.
• In April 2024, the U.S. Food and Drug Administration granted approval to nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC), in combination with Bacillus Calmette-Guérin (BCG), for adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) presenting with carcinoma in situ (CIS), with or without papillary tumors.
• In April 2024, the U.S. Food and Drug Administration (FDA) approved N-803, sold under the brand name Anktiva, for use alongside Bacillus Calmette-Guerin (BCG) immunotherapy. This approval allows for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer, enhancing the efficacy of immunotherapy.
• In 2024, the Health Resources and Services Administration (HRSA), agency of the U.S. Department of Health and Human Services is bolstering its Accelerating Cancer Screening (AxCS) Initiative with an additional investment of $10 million to bolster the Alcee L. Hastings Program for Advanced Cancer Screening, raising the total program funding to over $25 million within three years.
• The Canadian Pain Task Force (CPTF), offers guidance and insights to Health Canada, aimed at enhancing the strategies for preventing and managing chronic pain across the nation. In January 2021, the mandate of the CPTF was revitalized and expedited to provide recommendations on priority actions, with a primary focus on acknowledging and supporting individuals grappling with pain, while also emphasizing the necessity to understand, prevent, and effectively address pain throughout Canada.
• In January 2021, in Ontario, EMD Serono Canada and Pfizer Canada ULC announced that Health Canada has granted approval for BAVENCIO (avelumab). This approval is for the maintenance treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who have not experienced disease progression following initial platinum-based chemotherapy.
• Kauvery Hospital Alwarpet, a leading healthcare chain in Tamil Nadu, launches "Canvas of Hope," an art expo in partnership with Merck Specialty Pvt Ltd, to raise bladder cancer awareness through art. The hospital highlights the Urinary Fluorescent Flow Cytometry (UFFC) technology for quick and sensitive bladder cancer detection, a rarity in India, available at Kauvery Hospital.
• The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) is a significant health insurance scheme in India that provides coverage of up to INR 5 lakhs per family per year encompassing a wide range of medical treatments, including those related to cancer.

Bladder Cancer Market Key Trends

• The shift towards personalized medicine is becoming more prominent, with a focus on identifying specific biomarkers to tailor treatments to individual patients. This trend is enhancing the efficacy of treatments and reducing side effects, making therapies more effective and patient-centric.
• Advances in minimally invasive surgical techniques and technologies, such as robotic-assisted surgeries and endoscopic procedures, are gaining traction. These methods offer quicker recovery times, fewer complications, and improved patient quality of life.
• There is a growing trend towards using combination therapies to enhance treatment efficacy. Combining immunotherapies with chemotherapy or targeted therapies is showing promising results in clinical trials and is likely to become a standard approach in treating bladder cancer.
• The development of liquid biopsies for non-invasive cancer detection and monitoring is a significant trend. These tests can detect cancer-related biomarkers in blood or urine, allowing for earlier diagnosis and better monitoring of disease progression and treatment response.

Bladder Cancer Market COVID-19 Impact

The Bladder Cancer Market has been significantly impacted by the COVID-19 pandemic, witnessing major effects. One notable consequence has been the disruption in healthcare services, leading to delayed diagnoses and treatments for bladder cancer patients. Elective procedures and cancer screenings were affected, with hospital capacity constraints and resource reallocation further exacerbating delays.

For instance, findings from a study published in June 2022, titled "The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands," revealed a 14% decline in the number of bladder cancer (BC) diagnoses during the initial COVID wave. However, diagnosis rates rebounded to pre-pandemic levels by the end of 2020, with approximately 600 diagnoses per month. Despite these fluctuations, treatment modifications remained minimal and aligned with revised guidelines, ensuring that surgical volumes were not compromised during the first wave. Overall, the impact of the initial COVID-19 outbreaks on bladder cancer care in the Netherlands appeared less severe compared to other solid tumors documented locally and globally.

Similarly, updates from the American Urological Association's May 2022 report indicated significant care delays for bladder cancer patients in the United States during the peak of the COVID-19 pandemic in 2020. Over a quarter of bladder cancer patients, totaling 76,984 individuals (27.2%), reported alterations to their treatment plans, including changes, delays, or cancellations, due to the pandemic's effects. Specifically, 27.5% of bladder cancer patients experienced disruptions to their care. These disruptions, stemming from the pandemic's impact, notably affected the bladder cancer therapeutics and diagnostics market.

Moreover, the pandemic-induced disruptions extended to clinical trials investigating novel therapies for bladder cancer. Many trials were temporarily halted or delayed due to restrictions, impeding research progress and the regulatory approval of new treatments. This setback hindered innovation in the bladder cancer market and slowed down the development of potential breakthrough therapies.

Premium Insights

Globally, bladder cancer is becoming more common, which is a major factor driving market growth. For instance, according to the Global Cancer Observatory Statistics 2020, Bladder cancer ranks as the 10th most common cancer globally. It is the 6th most prevalent cancer among men and the 17th among women. In 2020, over 573,000 new cases of bladder cancer were reported worldwide.

The market is poised for rapid growth, driven by increasing awareness of bladder diseases and available treatments, coupled with expanding healthcare expenditure and the escalating burden of bladder cancer. For instance, in March 2022, the World Bladder Cancer Patient Coalition declared the 'Don't Go Red' theme for Bladder Cancer Awareness to raise awareness about warning signs and symptoms. Over the course of the projected period, initiatives such as these are anticipated to significantly enhance market growth.

The implementation of various strategic initiatives by key market players, including product launches and mergers and acquisitions, is poised to further propel market growth in the foreseeable future. For instance, Merck, known as MSD outside of the United States and Canada, announced a label update for KEYTRUDA, its anti-PD-1 treatment, in first-line advanced urothelial carcinoma (bladder cancer) in the United States. Such strategic moves by industry leaders are anticipated to contribute significantly to market expansion and innovation in bladder cancer therapeutics and diagnostics.

Supportive policy frameworks and regulations further add to market growth by encouraging innovation and simplifying market access. Pharmaceutical companies are encouraged to participate in bladder cancer research through the faster approval pathways for breakthrough treatments and incentives for research and development offered by regulatory agencies. In addition, public health campaigns and government-funded screening programs that increase awareness of bladder cancer led to better patient outcomes and early identification, which propels market growth.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Bladder Cancer Incidences Across Various Countries in 2022

According to World Cancer research Fund International, bladder cancer incidence and rates in 2022 where Spain recorded the highest overall rate of bladder cancer, followed by Italy

Bladder Cancer Mortality Across Various Countries in 2022

According to World Cancer research Fund International, bladder cancer mortality in 2022, where Egypt had the highest overall mortality rate from bladder cancer

Market Dynamics

Advancements in diagnostic technologies and the development of innovative treatment options are pivotal dynamics driving the growth of the market

Enhanced diagnostic technologies, such as improved imaging techniques, molecular diagnostics, and advanced cancer biomarker identification, enable earlier and more accurate detection of bladder cancer. The need for diagnostic technologies is growing since early detection is essential for successful treatment and better patient outcomes. The management of bladder cancer patients has been transformed by new and innovative therapeutic choices, including targeted treatments and immunotherapies. By concentrating on particular molecular targets connected to cancer cells, targeted therapies reduce harm to healthy cells and increase the effectiveness of treatment. Patients with advanced or resistant forms of bladder cancer have new hope because to immunotherapies, which use the body's immune system to combat disease. The ongoing advancement and validation of these pioneering treatments broaden the therapeutic horizon, fulfilling unfulfilled medical requirements and propelling the market's overall growth.

High costs associated with the disease and its management hinders market growth

The costs encompass various aspects, including diagnostic procedures, treatment modalities, supportive care, and follow-up services. Urine tests, imaging scans, and cystoscopies are examples of diagnostic tests that can be very expensive, particularly for people who don't have enough insurance. For patients and their families, bladder cancer treatment choices include surgery, chemotherapy, immunotherapy, and radiation therapy can also be quite expensive. The expenses related to prescription drugs, hospital stays, and supporting care add even more burden to the finances. Furthermore, the exorbitant expenses linked to the treatment of bladder cancer may present obstacles for healthcare professionals and institutions. For patients with bladder cancer, access to cutting-edge therapies and comprehensive care may be hampered by tight healthcare budgets, resource limitations, and payment regulations.

Bladder Cancer Market Competitive Landscape

The Bladder Cancer market is characterized by intense competition among leading pharmaceutical companies and biotech firms. Major players such as Merck & Co. F., Bristol-Myers Squibb, and Pfizer Inc. dominate the landscape with their innovative therapies and robust pipelines. These companies are heavily investing in research and development to introduce novel treatment options, including immunotherapies and targeted therapies, which are transforming the standard of care for bladder cancer patients. Additionally, collaborations and strategic partnerships are prevalent, enabling these firms to enhance their market presence and accelerate the development of cutting-edge treatments. Emerging companies and startups are also making significant strides in the bladder cancer market, bringing new technologies and approaches to diagnosis and treatment. The competitive environment is further fueled by advancements in precision medicine and biomarker research, which are driving personalized treatment plans. Regulatory approvals and favorable reimbursement policies are boosting market growth, creating opportunities for both established and new entrants.

The key players in the global Bladder Cancer market include - Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb, GlaxoSmithKline plc., Celgene Corporation, Sanofi S.A., Merck & Co., Eli Lilly and Company, AstraZeneca plc. among others.

Recent Developments

UroGen Pharma's UGN-102 Shows Promise in Bladder Cancer Treatment, ATLAS Study Reveals

• In May 2024, UroGen Pharma reports positive findings from analysis of UGN-102 in treating bladder cancer, showing comparable response rates at 12 months for new and recurrent patients. Results suggest potential for UGN-102 as primary treatment option, with Phase 3 ATLAS study demonstrating favorable outcomes compared to standard therapy.

FDA Consents to Evaluate ImmunityBio's N-803 BLA for Non-Muscle-Invasive Bladder Cancer

• In July 2022, the United States Food and Drug Administration (FDA) consented to evaluate ImmunityBio's Biologics License Application (BLA) for N-803, intended for patients with or without Ta or T1 illness who are diagnosed with non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).

Nanostics Inc. Launches Clinical Study for ClarityDX Bladder Test in Partnership with University of Alberta and DynaLIFE Medical Labs

• In 2022, Nanostics Inc. embarked on a prospective clinical study aimed at validating ClarityDX Bladder, a minimally invasive diagnostic test for bladder cancer, in collaboration with the University of Alberta’s APCaRI and DynaLIFE Medical Labs. This collaborative effort underscores the commitment to advancing precise and readily accessible diagnostic solutions for bladder cancer.

FDA Approves EPKINLYTM by AbbVie for Advanced Lymphoma Treatment Milestone in 2023

• In 2023, AbbVie achieved a significant milestone as the FDA granted approval for EPKINLYTM (epcoritamab-bysp), marking the first-ever sanction of a T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who have undergone two or more lines of systemic therapies.

The global Bladder Cancer market can be categorized as Type, Treatment, Major Tests, End User and Region.

Frequently Asked Questions (FAQs)?

1.How big is the market? What will be the global bladder cancer market size by 2032?

The global bladder cancer market is valued at $4.2 billion in 2023 and is anticipated to reach $6.04 billion by 2032, growing at a CAGR of 4.1% from 2024 to 2032.

2.Cystoscopy Vs Biopsy: Which Diagnostic Tool will lead the market?

Cystoscopy segment leads the market due to its high sensitivity and specificity in detecting early-stage bladder cancer, enabling timely intervention and improved patient outcomes. Additionally, cystoscopy is a cost-effective diagnostic method that is witnessing a surge in adoption, driven by the rising incidences of bladder cancer and continuous product innovations by key market players.

3.Is bladder cancer usually curable?

Early-stage bladder cancer is typically manageable with treatment but becomes more difficult to address as it progresses. Despite successful treatment, there is a risk of recurrence, underscoring the importance of ongoing surveillance following surgery or treatment.

4.What are the global incidences of bladder cancer?

Most bladder cancer cases occur in older individuals, with about 90% of patients being over the age of 55 at the time of diagnosis. On average, bladder cancer is diagnosed around the age of 73. In terms of lifetime risk, men have a higher likelihood of developing bladder cancer, with about 1 in 28 men expected to develop it during their lifetime. For women, the risk is lower, with approximately 1 in 89 women expected to be diagnosed with bladder cancer in their lifetime.

5.What percentage of cancers in the US does bladder cancer represent?

Bladder cancer constitutes approximately 4% of all cancers diagnosed in the United States. It ranks as the fourth most prevalent cancer in men, though it is less common in women

6.What are 5-year relative survival rates for bladder cancer?

5-year relative survival rates for bladder cancer, based on data from individuals diagnosed between 2013 and 2019, vary significantly by stage:

1. In situ alone: 96%
2. Localized (spread to nearby tissues or organs): 71%
3. Regional (spread to nearby lymph nodes or tissues): 39%
4. Distant (spread to distant organs or lymph nodes): 8%
5. Overall survival across all stages combined: 78%